Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17305606 | 1.00 | MEN1 (0.43) | MEN1KMT2AIDO1AGXTTBXAS1 | |
| SCHEMBL354135 | 0.87 | IDO1 (0.37) | IDO1AGXTTBXAS1CA1CA2 | |
| SCHEMBL354586 | 0.84 | MEN1 (0.46) | MEN1KMT2AIDO1AGXTTBXAS1 | |
| SCHEMBL13040466 | 0.83 | MEN1 (0.43) | MEN1KMT2AIDO1AGXTTBXAS1 | |
| SCHEMBL355605 | 0.82 | MEN1 (0.47) | MEN1KMT2AIDO1AGXTTBXAS1 | |
| SCHEMBL10100258 | 0.81 | MEN1 (0.37) | MEN1KMT2AIDO1AGXTTBXAS1 | |
| SCHEMBL17305607 | 0.81 | MEN1 (0.37) | MEN1KMT2AIDO1AGXTTBXAS1 | |
| SCHEMBL26512096 | 0.79 | CA1 (0.45) | IDO1AGXTTBXAS1CA1CA2 | |
| SCHEMBL7140177 | 0.74 | TBXAS1 (0.43) | IDO1AGXTTBXAS1CALM1 | |
| SCHEMBL13030081 | 0.74 | TBXAS1 (0.43) | IDO1AGXTTBXAS1CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827257-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-11-28 | — | — | US | disclosed |
| US-9750759-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2017-09-05 | — | — | US | disclosed |
| EP-2597091-B1 | Antitumoral Compounds | PHARMA MAR SA (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2015-12-03 | — | — | US | disclosed |
| US-9187445-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2015-11-17 | — | — | US | disclosed |
| US-8710264-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-04-29 | — | — | US | disclosed |
| EP-2231633-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-10-30 | — | — | EP | disclosed |
| US-8501968-B2 | Antitumoral dihydropyran-2-one compounds | PHARMAMAR, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| EP-2597091-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2013-05-29 | — | — | EP | disclosed |
| EP-2404912-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2404913-A2 | Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds | Pharma Mar S.A. (ES) | 2012-01-11 | — | — | EP | disclosed |
| EP-2032551-B1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR SA (ES) | 2011-08-31 | — | — | EP | disclosed |
| US-20110034549-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2011-02-10 | — | — | US | disclosed |
| US-20100280108-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-04 | — | — | US | disclosed |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-02-25 | — | — | US | disclosed |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-23 | — | — | US | disclosed |
| WO-2009080761-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080769-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-07-02 | — | — | WO | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344454-A1 | ANTITUMORAL COMPOUNDS | TP53, CCNY, RB1 | MEN1 221/4885KMT2A 1953/4885IDO1 1187/4885 |
| US-20100048690-A2 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | MEN1 1095/4885KMT2A 4182/4885IDO1 3750/4885 |
| US-20150342972-A1 | ANTITUMORAL COMPOUNDS | TP53, CCNY, RB1 | MEN1 221/4885KMT2A 1953/4885IDO1 1187/4885 |
| US-20090186938-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | RPLP1, PKD1, KRAS | MEN1 1095/4885KMT2A 4182/4885IDO1 3750/4885 |
| US-20100280108-A1 | Antitumoral Compounds | TPD52L2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53 | MEN1 191/4885KMT2A 2897/4885IDO1 2335/4885 |
| US-20110034549-A1 | Antitumoral Compounds | CCNY, RB1, TPD52L2 | MEN1 416/4885KMT2A 1976/4885IDO1 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.